Inclusion Criteria
Histologically or cytologically confirmed diagnosis of advanced cancer in patients with solid tumors that are refractory to standard treatment, or for whom no effective therapy exists
Organ function must be adequate
Exclusion Criteria
Has received systemic anti-cancer therapy within the 3 weeks prior to starting the trial
Has received radiotherapy within the 28 days prior to first dose or within 12 weeks for patients with glioblastoma, with the exception of palliative radiotherapy to focal lesions for pain or other symptom control
Has received major surgery within the 4 weeks prior to starting the trial
Has significant inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements
Clinically active known brain metastasis unless the brain metastases have been previously treated and are considered stable
Is pregnant or lactating
Had prior malignancy other than carcinoma in situ of the cervix or non-melanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 3 years previously with no subsequent evidence of recurrence
Has a known clinically significant GI disorder(s) including, but not limited to, inflammatory bowel disease or a history of extensive gastric resection and/or small intestinal resection
Has inability to take oral medications and/or has clinical or radiological diagnosis of bowel obstruction
Has had prior treatment with napabucasin